Supplementary table 1.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies
datasetposted on 2021-10-23, 12:04 authored by Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti
Supplementary Figure 1. Dose linearity and
proportionality in plasma following multiple doses of talazoparib.
Supplementary Table 1. Patient disposition by dose level and diagnosis (safety population).†
Supplementary Table 2. Exposure to talazoparib (safety population).